D&D PharmaTech's MASH Therapeutic DD01 Shows Promising Clinical Outcomes

According to a recent announcement from D&D PharmaTech, their investigational drug candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH), DD01, has achieved positive results in its Phase 2 clinical trial in the United States. Following the observed reduction in liver fat at week 12, favorable outcomes have also been reported from the 48-week liver biopsy assessment. This news offers a beacon of hope for MASH patients.

Phase 2 Results Exceed Expectations

D&D PharmaTech presented the 48-week liver biopsy results for DD01 from its Phase 2 clinical trial at the European Association for the Study of the Liver (EASL Congress 2026) annual meeting in Barcelona, Spain. The study was conducted across 12 clinical trial sites in the U.S. and was designed using a randomized, double-blind approach.

A total of 67 participants were enrolled in the trial, with the final liver biopsy efficacy analysis conducted on 35 individuals who met the study's criteria. The results showed that the proportion of patients with fibrosis improvement without MASH worsening in the DD01 treatment group was 34.2%p higher compared to the placebo group. Furthermore, patients achieving MASH resolution without fibrosis worsening were 57.2%p more numerous in the DD01 group.

Excellent Safety and Tolerability Profile

The safety profile of DD01 also received positive evaluations. The drug demonstrated good tolerability throughout the 48-week treatment period. The most frequently reported adverse events were primarily gastrointestinal in nature, and these symptoms were mostly mild to moderate, transient, and resolved over time.

Potential as a Next-Generation MASH Therapeutic

D&D PharmaTech CEO, Lee Seul-gi, stated, "Despite the relatively limited number of patients, differentiated histological improvement effects were confirmed." He expressed confidence that DD01 will further solidify its competitiveness as a next-generation MASH therapeutic, marking a significant turning point in providing new treatment options for MASH patients.

These study findings bring new hope to MASH patients, and further research and clinical trials for DD01 are highly anticipated. It will be worth watching to see what achievements D&D PharmaTech will continue to make in this field.